v3.26.1
Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2026
License Agreements [Member]  
Intangible Asset, Finite-Lived [Line Items]  
Components of Intangible Assets

The components of intangible assets were as follows (in thousands):

 

 

 

June 30, 2026

 

 

December 31, 2025

 

 

 

Gross Carrying

 

 

Accumulated

 

 

Net Carrying

 

 

Gross Carrying

 

 

Accumulated

 

 

Net Carrying

 

 

 

Value

 

 

Amortization

 

 

Value

 

 

Value

 

 

Amortization

 

 

Value

 

License Agreements

 

$

3,117

 

 

$

(2,477

)

 

$

640

 

 

$

3,117

 

 

$

(2,366

)

 

$

751

 

Estimated Future Amortization Expense Related to Intangible Assets The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2026 (in thousands):

 

Year Ending December 31,

 

 

 

2026

 

 

112

 

2027

 

 

223

 

2028

 

 

223

 

2029

 

 

82

 

Total

 

$

640

 

Domain Name Defensive [Member]  
Intangible Asset, Finite-Lived [Line Items]  
Components of Intangible Assets

As of June 30, 2026, the domain name intangible assets consisted of the following:

 

 

 

June 30, 2026

 

 

December 31, 2025

 

 

 

Gross Carrying

 

 

Accumulated

 

 

Net Carrying

 

 

Gross Carrying

 

 

Accumulated

 

 

Net Carrying

 

 

 

Value

 

 

Amortization

 

 

Value

 

 

Value

 

 

Amortization

 

 

Value

 

Domain Names

 

$

170

 

 

$

(1

)

 

$

169

 

 

$

 

 

$

 

 

$

 

Estimated Future Amortization Expense Related to Intangible Assets

The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2026 (in thousands):

 

Year Ending December 31,

 

 

 

2026

 

 

6

 

2027

 

 

12

 

2028

 

 

12

 

2029

 

 

12

 

2030

 

 

12

 

Thereafter

 

 

115

 

Total

 

$

169

 

 

Intangible Assets Impairment Analysis

 

We evaluate the carrying amount of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful life or that indicate the asset may be impaired. We conducted an analysis of potential impairment indicators for long lived assets, including the license and supply agreements for the active pharmaceutical ingredient cytisinicline and Domain Name Defensive Intangible Assets, and concluded that there were no indicators of impairment identified as of June 30, 2026.